{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T02:06:27Z","timestamp":1791511587310,"version":"4.3.4"},"reference-count":37,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T00:00:00Z","timestamp":1715126400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.ijantimicag.2024.107196","type":"journal-article","created":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T07:11:08Z","timestamp":1715325068000},"page":"107196","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Characterising the blood-stage antimalarial activity of pyronaridine in healthy volunteers experimentally infected with Plasmodium falciparum"],"prefix":"10.1016","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1066-7960","authenticated-orcid":false,"given":"Bridget E.","family":"Barber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Webster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam J.","family":"Potter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0564-947X","authenticated-orcid":false,"given":"Stacey","family":"Llewellyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nischal","family":"Sahai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Indika","family":"Leelasena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Mathison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5452-8957","authenticated-orcid":false,"given":"Karsten","family":"Kuritz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Flynn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9306-1851","authenticated-orcid":false,"given":"Stephan","family":"Chalon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Claire","family":"Marrast","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Gobeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0769-9649","authenticated-orcid":false,"given":"Joerg J.","family":"Moehrle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2024.107196_bib0001","series-title":"World malaria report 2023","year":"2023"},{"issue":"5","key":"10.1016\/j.ijantimicag.2024.107196_bib0002","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1314981","article-title":"Spread of artemisinin resistance in Plasmodium falciparum malaria","volume":"371","author":"Ashley","year":"2014","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.ijantimicag.2024.107196_bib0003","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1056\/NEJMoa2101746","article-title":"Evidence of artemisinin-resistant malaria in Africa","volume":"385","author":"Balikagala","year":"2021","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.ijantimicag.2024.107196_bib0004","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa2211803","article-title":"Evolution of partial resistance to artemisinins in malaria parasites in Uganda","volume":"389","author":"Conrad","year":"2023","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.ijantimicag.2024.107196_bib0005","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1056\/NEJMoa2210956","article-title":"Increasing prevalence of artemisinin-resistant HRP2-negative malaria in Eritrea","volume":"389","author":"Mihreteab","year":"2023","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.ijantimicag.2024.107196_bib0006","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/s41573-023-00772-9","article-title":"Antimalarial drug discovery: progress and approaches","volume":"22","author":"Siqueira-Neto","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.ijantimicag.2024.107196_bib0007","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1186\/1475-2875-11-270","article-title":"Review of pyronaridine anti-malarial properties and product characteristics","volume":"11","author":"Croft","year":"2012","journal-title":"Malar J"},{"issue":"4","key":"10.1016\/j.ijantimicag.2024.107196_bib0008","doi-asserted-by":"crossref","first-page":"e23398","DOI":"10.1002\/bip.23398","article-title":"Pyronaridine: an update of its pharmacological activities and mechanisms of action","volume":"112","author":"Bailly","year":"2021","journal-title":"Biopolymers"},{"key":"10.1016\/j.ijantimicag.2024.107196_bib0009","unstructured":"Pyramax: opinion on medicine for use outside EU, https:\/\/www.ema.europa.eu\/en\/opinion-medicine-use-outside-EU\/human\/pyramax [accessed 28.08.23]."},{"key":"10.1016\/j.ijantimicag.2024.107196_bib0010","series-title":"WHO guidelines for malaria, 14 March 2023","year":"2023"},{"issue":"10","key":"10.1016\/j.ijantimicag.2024.107196_bib0011","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1093\/jac\/dkad260","article-title":"Pyronaridine: a review of its clinical pharmacology in the treatment of malaria","volume":"78","author":"Chu","year":"2023","journal-title":"J Antimicrob Chemothe"},{"issue":"8993","key":"10.1016\/j.ijantimicag.2024.107196_bib0012","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/S0140-6736(96)91558-5","article-title":"Randomised trial of pyronaridine versus chloroquine for acute uncomplicated falciparum malaria in Africa","volume":"347","author":"Ringwald","year":"1996","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ijantimicag.2024.107196_bib0013","doi-asserted-by":"crossref","first-page":"205","DOI":"10.4269\/ajtmh.1996.54.205","article-title":"Clinical study of pyronaridine for the treatment of acute uncomplicated falciparum malaria in Thailand","volume":"54","author":"Looareesuwan","year":"1996","journal-title":"Am J Trop Med Hyg"},{"issue":"11","key":"10.1016\/j.ijantimicag.2024.107196_bib0014","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1093\/cid\/ciad075","article-title":"Characterizing the blood stage antimalarial activity of tafenoquine in healthy volunteers experimentally infected with Plasmodium falciparum","volume":"76","author":"Barber","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.ijantimicag.2024.107196_bib0015","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/S1473-3099(21)00679-4","article-title":"Safety, pharmacokinetics, and antimalarial activity of the novel triaminopyrimidine ZY-19489: a first-in-human, randomised, placebo-controlled, double-blind, single ascending dose study, pilot food-effect study, and volunteer infection study","volume":"22","author":"Barber","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"10.1016\/j.ijantimicag.2024.107196_bib0016","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S1473-3099(17)30171-8","article-title":"Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a\/1b randomised study","volume":"17","author":"McCarthy","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2024.107196_bib0017","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1186\/s12936-016-1511-3","article-title":"A phase II pilot trial to evaluate safety and efficacy of ferroquine against early Plasmodium falciparum in an induced blood-stage malaria infection study","volume":"15","author":"McCarthy","year":"2016","journal-title":"Malar J"},{"issue":"1","key":"10.1016\/j.ijantimicag.2024.107196_bib0018","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S1473-3099(15)00320-5","article-title":"Antimalarial activity of artefenomel (OZ439), a novel synthetic antimalarial endoperoxide, in patients with Plasmodium falciparum and Plasmodium vivax malaria: an open-label phase 2 trial","volume":"16","author":"Phyo","year":"2016","journal-title":"Lancet Infect Dis"},{"issue":"8","key":"10.1016\/j.ijantimicag.2024.107196_bib0019","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/S1473-3099(18)30309-8","article-title":"Antimalarial activity of single-dose DSM265, a novel plasmodium dihydroorotate dehydrogenase inhibitor, in patients with uncomplicated Plasmodium falciparum or Plasmodium vivax malaria infection: a proof-of-concept, open-label, phase 2a study","volume":"18","author":"Llanos-Cuentas","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2024.107196_bib0020","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/1475-2875-10-48","article-title":"A real-time, quantitative PCR method using hydrolysis probes for the monitoring of Plasmodium falciparum load in experimentally infected human volunteers","volume":"10","author":"Rockett","year":"2011","journal-title":"Malar J"},{"issue":"1","key":"10.1016\/j.ijantimicag.2024.107196_bib0021","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1186\/s12936-020-03291-9","article-title":"Assays for quantification of male and female gametocytes in human blood by qRT-PCR in the absence of pure sex-specific gametocyte standards","volume":"19","author":"Wang","year":"2020","journal-title":"Malar J"},{"issue":"1","key":"10.1016\/j.ijantimicag.2024.107196_bib0022","doi-asserted-by":"crossref","first-page":"188","DOI":"10.4269\/ajtmh.16-0893","article-title":"Molecular markers for sensitive detection of Plasmodium falciparum asexual stage parasites and their application in a malaria clinical trial","volume":"97","author":"Tadesse","year":"2017","journal-title":"Am J Trop Med Hyg"},{"issue":"7","key":"10.1016\/j.ijantimicag.2024.107196_bib0023","doi-asserted-by":"crossref","first-page":"4249","DOI":"10.1128\/AAC.04942-14","article-title":"Evaluating the pharmacodynamic effect of antimalarial drugs in clinical trials by quantitative PCR","volume":"59","author":"Marquart","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.ijantimicag.2024.107196_bib0037","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1186\/s12936-021-03717-y","article-title":"Analytical validation of a real-time hydrolysis probe PCR assay for quantifying Plasmodium falciparum parasites in experimentally infected human adults","volume":"20","author":"Wang","year":"2021","journal-title":"Malar J"},{"issue":"1","key":"10.1016\/j.ijantimicag.2024.107196_bib0024","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/infdis\/jiw128","article-title":"Piperaquine monotherapy of drug-susceptible Plasmodium falciparum infection results in rapid clearance of parasitemia but Is followed by the appearance of gametocytemia","volume":"214","author":"Pasay","year":"2016","journal-title":"J Infect Dis"},{"issue":"8","key":"10.1016\/j.ijantimicag.2024.107196_bib0025","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003203","article-title":"Safety and parasite clearance of artemisinin-resistant Plasmodium falciparum infection: a pilot and a randomised volunteer infection study in Australia","volume":"17","author":"Watts","year":"2020","journal-title":"PLoS Med"},{"key":"10.1016\/j.ijantimicag.2024.107196_bib0026","series-title":"Pharmacokinetics of pyronaridine in adult and pediatric populations","author":"Ayyoub","year":"2016"},{"key":"10.1016\/j.ijantimicag.2024.107196_bib0027","series-title":"Population pharmacokinetics and pharmacodynamics of pyronaridine","author":"Methaneethorn","year":"2013"},{"key":"10.1016\/j.ijantimicag.2024.107196_bib0028","series-title":"Population pharmacokinetics of pyronaridine in the treatment of malaria","author":"Wattanavijitkul","year":"2010"},{"issue":"3","key":"10.1016\/j.ijantimicag.2024.107196_bib0029","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1128\/AAC.02004-15","article-title":"Population pharmacokinetics of pyronaridine in pediatric malaria patients","volume":"60","author":"Ayyoub","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2024.107196_bib0030","article-title":"Characterizing the pharmacological interaction of the antimalarial combination artefenomel-piperaquine in healthy volunteers with induced blood stage Plasmodium falciparum","author":"Abd-Rahman","year":"2024","journal-title":"medRxiv"},{"issue":"4","key":"10.1016\/j.ijantimicag.2024.107196_bib0031","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02181-19","article-title":"Preclinical antimalarial combination study of M5717, a Plasmodium falciparum elongation factor 2 inhibitor, and pyronaridine, a hemozoin formation inhibitor","volume":"64","author":"Rottmann","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"7556","key":"10.1016\/j.ijantimicag.2024.107196_bib0032","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nature14451","article-title":"A novel multiple-stage antimalarial agent that inhibits protein synthesis","volume":"522","author":"Baragana","year":"2015","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.ijantimicag.2024.107196_bib0033","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/S1473-3099(21)00252-8","volume":"21","author":"McCarthy","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"10.1016\/j.ijantimicag.2024.107196_bib0034","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003669","article-title":"Pyronaridine-artesunate real-world safety, tolerability, and effectiveness in malaria patients in 5 African countries: a single-arm, open-label, cohort event monitoring study","volume":"18","author":"Tona Lutete","year":"2021","journal-title":"PLoS Med"},{"issue":"10128","key":"10.1016\/j.ijantimicag.2024.107196_bib0035","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1016\/S0140-6736(18)30291-5","article-title":"Pyronaridine-artesunate or dihydroartemisinin-piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b\/4 trial","volume":"391","year":"2018","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ijantimicag.2024.107196_bib0036","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1186\/s12936-021-04003-7","article-title":"Haematological response in experimental human Plasmodium falciparum and Plasmodium vivax malaria","volume":"20","author":"Woolley","year":"2021","journal-title":"Malar J"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857924001146?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857924001146?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,16]],"date-time":"2024-06-16T07:39:40Z","timestamp":1718523580000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857924001146"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S0924857924001146"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2024.107196","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characterising the blood-stage antimalarial activity of pyronaridine in healthy volunteers experimentally infected with Plasmodium falciparum","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2024.107196","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107196"}}